PharmaIntellect - Pharma Deals

by Unknown on Saturday, 1 June 2013

PharmaIntellect - Pharma Deals

Link to PharmaIntellect - Pharma Deals

BeiGene outlicenses Global development and commercialization rights (ex-China) for its novel BRAF inhibitor to Merck KGAA

Posted: 01 Jun 2013 12:56 AM PDT

BeiGene Co., Ltd.  a biotech R&D company in Beijing, and Merck KGaA, Darmstadt, Germany,  have entered into a global licensing, co-development, and commercialization agreement for BeiGene-283. ...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Leave a Reply

Popular Posts